JNJJanssen Research & Development, LLCRunning, no new patients
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
Carcinoma, Non-Small-Cell Lung
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 68 (final count)
- Started
- May 18, 2023
- Main results expected
- Mar 29, 2024
- Fully finished
- Sep 30, 2027
- Results posted
- Oct 20, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants With Infusion-related Reactions (IRRs) at Cycle 1 Day 1
Measured over: Cycle 1 Day 1 (each cycle of 28 days)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05663866 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC